R

Roche

Global pharmaceuticals and diagnostics company

Finance Excellence Partner

Full-TimeUpdated on 10/22/2026Deadline 10/23/26
No salary listed
Senior
Bachelor's
Johannesburg, South Africa
In Person
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • At least 7 years of working experience and a solid understanding of management and financial accounting and affiliate finance.
  • A degree in Finance, Accounting, Economics, Business Administration, or a related field.
  • Ability to work across affiliates, subregions, and regions in an end-to-end networked environment with an enterprise perspective.
  • Customer orientation, analytical skills, proactivity, and adaptability to change.
  • Good business understanding to drive innovation and performance.
  • Advanced controlling and reporting skills and expertise with the system landscape used by affiliates, including business intelligence tools such as Tableau.
  • Strong SAP and Microsoft Office knowledge, particularly Excel.
  • Effective communication and stakeholder management skills.
  • Excellent verbal and written communication skills in English.
  • Demonstrated experience with agile ways of working.
  • Ability to manage multiple priorities.
  • Strong problem-solving and solution-oriented abilities.
  • High self-motivation and reliability.
  • Excellent technical skills in Finance and Accounting.
  • Entrepreneurial perspective and enterprise thinking.
  • Systems thinking and understanding interdependencies within and above the affiliate.
  • Growth, Agile, and Experimental mindset and ability to constructively challenge the status quo.
Responsibilities
  • Serve as the affiliate liaison to stakeholders across the global Roche finance environment, including eCoE and Roche Shared Services.
  • Drive local affiliate adoption of developed, automated, and enhanced standard global management reporting solutions to support business operations and needs.
  • Ensure information flow and cooperate with local Finance Enterprise Partners to find common solutions for Finance backbone operations, increase customer satisfaction, and optimize internal procedures.
  • Monitor finance processes to assure financial compliance, including implementation of ICFR controls by designated control owners.
  • Identify and analyze process inefficiencies and drive continuous improvements through standardized processes across the Middle East and Africa subregions.
  • Coordinate and set the process, timeline, and clarity of deliverables for annual budget processes for local and subregional organizations.
  • Plan the annual OPEX budget and track and analyze actual performance against budget, forecasts, and KPIs.
  • Support cleaning and alignment of financial master data in collaboration with master data owners.
  • Use technology and automation to drive digitalization and explore and apply new technologies and tools in automation and AI.
  • Drive the transition of affiliate-focused finance operations toward above-affiliate-level operations in line with Finance ambitions.
  • Contribute to activities and projects on the above-affiliate level as an active member of the MEA Finance Excellence Chapter.
  • Participate in an above-affiliate backup plan in Middle East and Africa subregions to ensure business continuity.
  • Serve as an expert in dedicated Roche processes, systems, tools, and Finance Excellence Partner tasks by supporting the MEA chapter with consultancy, troubleshooting, best-practice definition, and continuous learning.
  • Participate in squads and cross-chapter teams to address high-priority projects with end-to-end responsibility.
Desired Qualifications
  • SAICA qualification is highly preferred.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.